Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
Recent News
Press Kit
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.


Nutra Pharma Announces Grupo Farmaceutico de Tijuana as its Exclusive Nyloxin Distributor in Mexico
June 10, 2010

Nutra Pharma has selected Grupo Farmacéutico de Tijuana to serve as the exclusive distributor in Mexico for its Nyloxin-branded pain relievers.

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that Grupo Farmacéutico de Tijuana (GFT) has become the exclusive Mexican distributor for  the Company’s Nyloxin-branded pain relievers, Nyloxin OTC and Nyloxin Rx.

“We are pleased to announce our partnership with GFT as our exclusive Nyloxin distributor in Mexico and our very first International partner,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “GFT is a highly regarded healthcare products distributor that can provide the resources and distribution capabilities needed to successfully launch Nyloxin throughout Mexico,” he concluded.

Grupo Farmacéutico de Tijuana (GFT), which was founded in 1955, currently operates two primary distribution facilities; one in Monterrey Nuevo Leon, to service Midwestern and southeastern Mexico and another in the city of Tijuana to service the northwest. In addition to distributing pharmaceutical products to large, national retailers, the Company also distributes to over 3,000 pharmacies throughout Mexico.

“We are excited about our partnership with Nutra Pharma to introduce Nyloxin to Mexico. Combining the product’s effectiveness with our distribution strategies will allow us to create a greater impact as we move forward with our launch,” commented Enrique A. Fajardo, Managing Director of Grupo Farmacéutico de Tijuana. “This alliance will be an opportunity for both of our companies to provide an all-natural pain management solution to the Mexican consumer,” he added.

In addition to partnering with GFT for Nyloxin distribution throughout Mexico, Nutra Pharma recently announced its agreement with leading healthcare products distributor, Henry Schein, for distribution of Nyloxin in the United States.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. Partnering with Grupo Farmacéutico de Tijuana for distribution in Mexico should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at  Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.


Recent News
August 03, 2017
New Edition of Textbook on Treating Canine Arthritis Includes Nutra Pharma Pain Remedy

June 21, 2017
Nutra Pharma Announcing Launch of Luxury Feet

June 07, 2017
Nutra Pharma Featured on Univision's Spanish-Language News Show: Primer Impacto

Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
Facebook   Twitter
Privacy Policy Code of Ethics